Patents by Inventor Soren Ljungberg PEDERSEN

Soren Ljungberg PEDERSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250002544
    Abstract: The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.
    Type: Application
    Filed: June 24, 2024
    Publication date: January 2, 2025
    Inventors: Peter Wilhelm HAEBEL, Albert BRENNAUER, Charlotte Stahl MADSEN, Soren Ljungberg PEDERSEN, Stefan PETERS
  • Patent number: 12139520
    Abstract: The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50?250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (hAMY3R) agonists (hAMY3R-EC50?250 pM and an hAM1R-EC50?25 nM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The hAM15-52 analogues according to the invention maintain the good physical stability of hAM15-52. The invention further relates to pharmaceutical compositions comprising such polypeptides and their use in the treatment of a medical condition such as obesity, NASH and/or diabetes.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: November 12, 2024
    Assignee: GUBRA A/S
    Inventors: Jens Christian Frøslev Nielsen, Kristoffer Tobias Gustav Rigbolt, Esben Matzen Bech, Morten Lundh, Paola Magotti, Borja Ballarín-González, Søren Ljungberg Pedersen, Niels Vrang
  • Patent number: 12054525
    Abstract: The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: August 6, 2024
    Assignee: Boehringer Ingelheim Internatioal GmbH
    Inventors: Peter Wilhelm Haebel, Albert Brennauer, Charlotte Stahl Madsen, Soren Ljungberg Pedersen, Stefan Peters
  • Publication number: 20240101634
    Abstract: The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50?250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (hAMY3R) agonists (hAMY3R-EC50?250 pM and an hAM1R-EC50?25 nM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The hAM15-52 analogues according to the invention maintain the good physical stability of hAM15-52. The invention further relates to pharmaceutical compositions comprising such polypeptides and their use in the treatment of a medical condition such as obesity, NASH and/or diabetes.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 28, 2024
    Applicant: GUBRA A/S
    Inventors: Jens Christian Frøslev NIELSEN, Kristoffer Tobias, Gustav RIGBOLT, Esben Matzen BECH, Morten LUNDH, Paola MAGOTTI, Borja BALLARiN-GONZÁLEZ, Søren Ljungberg PEDERSEN, Nieis VRANG
  • Publication number: 20230340039
    Abstract: The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.
    Type: Application
    Filed: December 20, 2022
    Publication date: October 26, 2023
    Inventors: Peter Wilhelm HAEBEL, Albert BRENNAUER, Charlotte Stahl MADSEN, Soren Ljungberg PEDERSEN, Stefan PETERS
  • Publication number: 20220041678
    Abstract: The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.
    Type: Application
    Filed: August 5, 2021
    Publication date: February 10, 2022
    Inventors: Peter Wilhelm HAEBEL, Albert BRENNAUER, Stefan PETERS, Charlotte Stahl MADSEN, Søren Ljungberg PEDERSEN
  • Publication number: 20210139548
    Abstract: The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 13, 2021
    Inventors: Peter Wilhelm HAEBEL, Albert BRENNAUER, Charlotte Stahl MADSEN, Soren Ljungberg PEDERSEN, Stefan PETERS
  • Publication number: 20190336610
    Abstract: The present invention relates to a conjugate of the formula P-L-I, wherein P is a peptide hormone effecting the metabolism of carbohydrates in vivo, L is a hydrolysable linker molecule consisting of Lp and Li, and I is a molecule capable of inhibiting the effect of the peptide hormone P on the metabolism of carbohydrates in vivo. Under in vivo conditions, the conjugate is the major compound. When the concentration of glucose increases in vivo, the concentration of the peptide hormone effecting the metabolism of carbohydrates in vivo also increases.
    Type: Application
    Filed: December 22, 2017
    Publication date: November 7, 2019
    Applicant: GUBRA APS
    Inventors: Knud Jørgen JENSEN, Charlotte Stahl MADSEN, Karin Margareta Sophia MANNERSTEDT, Esben Matzen BECH, Søren Ljungberg PEDERSEN, Jacob JELSING, Niels VRANG
  • Publication number: 20180280480
    Abstract: The present invention relates to compositions and peptides having agonist activity towards both the human GLP-1 receptor and the human GLP-2 receptor, wherein the relative agonist activity of the dual peptide towards the human GLP-1 receptor (GLP-1Rrelative) is at least 0.01, and wherein the relative agonist activity of the dual peptide towards the human GLP-2 receptor (GLP-2rrelative) is at least 0.01, and wherein (GLP-1Rrelative)(GLP-2Rrelative) is at least 0.01, as well as methods of production and uses thereof. Further, the invention relates to lipidated analogs of the peptides. The invention further relates to the treatment or prophylactic treatment of human diseases, in particular gut and brain relates diseases or metabolic disorders, such as gastrointestinal inflammation, short bowel syndrome and Crohn's disease.
    Type: Application
    Filed: October 30, 2015
    Publication date: October 4, 2018
    Applicant: GUBRA ApS
    Inventors: Søren Ljungberg PEDERSEN, Søren Blok Van WITTELOOSTUJN, Pernille KONGSBAK-WISMANN, Jacob JELSING, Niels VRANG